Based in New York City, Marcel will help strengthen our capabilities in the US and Asian markets by helping our clients to … Kasznar Leonardos welcomes Marcel Nadal Michelman as our Of Counsel in the USA
With more than 20 years' experience in legal and intellectual property areas, Maria Pia Guerra has joined our firm as Executive Director of our international unit I’B The IP Hub
Rosane Tavares has more than 30 years' experience in Intellectual Property.
On April 17, 2018 the Superior Court of Justice had the opportunity to analyze the first Special Appeal addressing the term of … Brazilian Superior Court of Justice decides its first mailbox case
In a decision made available on the 7th of November, Judge of the Supreme Court Luiz Fux dismissed a lawsuit by which … Supreme Court dismisses lawsuit against rule that guarantees a minimum term for patent protection
On August 8 2017 ANVISA officially published the new Rule RDC Nº 168, related to the prior consent of the Agency on patent applications for pharmaceutical products and processes, regulated by Joint Ordinance ANVISA-INPI No. 1, dated April 12, 2017, aiming to a more efficient way to analyze patent applications.
ANVISA has published, on 08/02/2017, in the Federal Register, the the Public Consultation 371/2017 to discuss the extension, from 5 to 10 … Medical Devices – ANVISA´s Public Consultation to extend the registration term
The Ministry of Industry and Commerce (MDIC) and the Brazilian Patent and Trademark Office (INPI) have opened for Public Consultation a Proposal for a Resolution to regulate a simplified allowance procedure for patent applications in Brazil, aiming to deal in a swift manner with the ever increasing backlog of patent applications awaiting examination, currently exceeding the figure of 230.000.
The Ministry of Industry and Commerce (MDIC) and the Brazilian Patent and Trademark Office (INPI) have opened for Public Consultation a Proposal for a Resolution to regulate a simplified allowance procedure for patent applications in Brazil, aiming to deal in a swift manner with the ever increasing backlog of patent applications awaiting examination, currently exceeding the figure of 230.000.
Allergan had obtained an injunction preventing the marketing of a generic drug for Combingan®. However, such injunction was revoked because the Trial … São Paulo Court allows the marketing of generic drug while the patent applications for the reference drug are still pending
